logo
Plus   Neg
Share
Email

Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis

Gilead Sciences Inc. (GILD) said Friday that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses.

As per the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets.

Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales.

Gilead said its antiviral portfolio includes among the most widely used medicines for the treatment of HIV, hepatitis B and hepatitis C, as well as influenza infection.

Separately, Novartis said that the Chinese National Medical Products Administration approved Gilenya for relapsing forms of multiple sclerosis for adults and children 10 years and older.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney Co. (DIS) Tuesday announced CEO Robert Iger will step down immediately, and will be replaced by Bob Chapek. Chapek most recently served as Chairman of Disney Parks, Experiences and Products. Iger will assume the role of Executive Chairman and will "direct the company's creative endeavors,"... Shares of Salesforce.com Inc. (CRM) slipped nearly 3% in after-hours trading Tuesday. The cloud-based enterprise software marker reported a fourth-quarter profit that trumped Wall Street estimates as did its revenues. However, the company announced that its co-Chief Executive Keith Block is stepping... Home Depot Inc. (HD) on Tuesday reported 5.8 percent increase in fourth-quarter profit, while Macy's Inc. (M) fourth-quarter profit fell 54.1 percent. However, the results of the companies beat analysts' estimates. The retailers have reaffirmed their annual outlook.
Follow RTT
>